Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 3Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Diseases 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Papillomavirus Infections 1Neoplasms 1Genital Diseases, Female 1

Interventions

Paclitaxel 489Carboplatin 435Gemcitabine 394Docetaxel 385Cisplatin 359pembrolizumab 343Bevacizumab 335Nivolumab 261Pemetrexed 242Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 91

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × INDUSTRY × GX-188 vaccine × Clear all
NCT03444376 2025-07-30

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Genexine, Inc.

Phase 1/2 Completed
65 enrolled 16 charts
Gynecologic

Uterine Cervical Neoplasms

NCT02139267 2017-07-12

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Genexine, Inc.

Phase 2 Completed
72 enrolled
Gynecologic

Uterine Cervical Dysplasia, Genital Diseases, Female, Neoplasms, Uterine Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡